ClinicalTrials.gg
Active, not recruitingNCT06040099EMERALD-Y90Updated Sep 21, 2026

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

A Phase 2 interventional study of Durvalumab and Bevacizumab in Hepatocellular Carcinoma (HCC), sponsored by AstraZeneca. Active, not recruiting at 21 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing durvalumab in Carcinoma, Hepatocellular — 22 open to participants now, 32 under way, 4 of them phase 3. durvalumab · Carcinoma, Hepatocellular.

Enrollment
14th of 42
58 · median 37
Started
2024
with 6 others
Phase 2
28 of 42
15 open now
Primary completion
2026-06
later than 11 of 31 live
Registered
27th of 42
by date
Lead sponsor
7 of 42
AstraZeneca

Among the 42 studies testing durvalumab in Carcinoma, Hepatocellular, this one is the 14th largest by enrollment, is one of 7 that started in 2024, is one of 28 in phase 2, reaches primary completion later than 11 of the 31 other live ones, and was the 27th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

22 of the 42 studies testing durvalumab in Carcinoma, Hepatocellular are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing durvalumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.

Read the detailed description

A Phase II single-arm study conducted in participants with unresectable Hepatocellular carcinoma (HCC) eligible for embolization and not eligible for or who have declined treatment with resection and/or ablation or liver transplant.

Participants with previous Transarterial Chemoembolization (TACE) or TARE associated with the curative setting are permitted with a 6-month washout.

Approximately 120 participants with unresectable but amenable to locoregional therapy HCC eligible for embolization will be screened in the study at approximately 20 sites in the US to enroll approximately 60 participants.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • TARE
  • Durvalumab
  • Bevacizumab
  • Liver Cancer
  • Y90
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with confirmed unresectable HCC
  • Participants with Lung dose threshold for Yttrium 90 glass microspheres of 30 Gy (equal or less than 30 Gy per treatment for glass) and an estimated Future liver remnant volume (FLRV) ≥ 30% of whole liver volume.
  • Participants with more than 1 prior embolization are permitted if more than 12 months ago, for a different primary lesion, and FLR > 30%.
  • Participants with no evidence of extrahepatic disease on any available imaging
  • Participants with one or more , unilobar disease for participants with segmental or right anterior/posterior portal vein invasion (Vp1/Vp2) and eligible for Yttrium 90 glass microspheres TARE.
  • Participants having score class A.
  • Participants having performance status of 0 or 1 at enrollment
  • Adequate organ and marrow function

Exclusion criteria

Exclusion Criteria:

  • Disease amenable to curative surgery, ablation or transplantation. Transplant patients are considered eligible if outside of Milan criteria and not currently listed for transplant.
  • Participants co-infected with and HDV
  • Any history of nephrotic or nephritic syndrome.
  • (eg, active) cardiovascular disease
  • Participants with uncontrolled hypertension
  • History of hepatic encephalopathy
  • Known hereditary predisposition to bleeding or thrombosis; any prior or current evidence of bleeding diathesis.
  • Receipt of more than 1 prior embolization (TACE or TARE) treatment/procedure
  • Participant has received any prior anticancer systemic therapy for unresectable HCC.
  • History of arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or , within 6 months prior to enrollment.
  • History of abdominal fistula or gastrointestinal (GI) perforation, non-healed gastric ulcer that is to treatment, or active GI bleeding within 6 months prior to enrollment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Yttrium 90 glass microspheres TARE in combination with Durvalumab and Bevacizumab

    Participants will undergo Yttrium 90 glass microspheres TARE according to the dosimetry recommendation.

    Drug: Durvalumab · Drug: Bevacizumab · Procedure: Transarterial Radioembolization (TARE)

Interventions

  • Durvalumab IV (intravenous)

    Also known as: MEDI4736, IMFINZI

  • Bevacizumab IV (intravenous)

    Also known as: AVASTIN, ZIRABEV

  • ProcedureTransarterial Radioembolization (TARE)

    Yttrium 90 glass microspheres will be administered

    Also known as: TheraSphere

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from Day 1 (day of TARE) until the date of progressive disease per modified Response Evaluation Criteria in Solid Tumors (mRECIST), as assessed by the investigator, or death due to any cause. It is measured to assess the efficacy of TARE followed by durvalumab monotherapy followed by durvalumab + bevacizumab in participants with unresectable HCC amenable to locoregional therapy.

    Time frame: From Day 1 until date of progressive disease or death [Approximately 3 years]

Secondary outcomes

  1. Number of participants with Adverse events (AEs)

    To assess the safety of the sequence of TARE followed by durvalumab monotherapy followed by durvalumab + bevacizumab in participants with unresectable HCC amenable to locoregional therapy

    Time frame: From Screening (Day -28 to Day 1) until 90 days after the last dose of study drug

  2. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants who have a confirmed complete response or partial response, as determined by the investigator per mRECIST. It is assessed after TARE followed by durvalumab monotherapy followed by durvalumab + bevacizumab in participants with unresectable HCC amenable to locoregional therapy.

    Time frame: From Day 1 until progression, or the last evaluable assessment in the absence of progression (Approximately 3 years)

  3. Overall Survival (OS)

    OS is defined as the time from the start of TARE until the date of death due to any cause. It is assessed after TARE followed by durvalumab monotherapy followed by durvalumab + bevacizumab in participants with unresectable HCC amenable to locoregional therapy.

    Time frame: Day 1 to 18 months or until death (Approximately 3 years)

  4. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented response (that is subsequently confirmed) until the date of documented progression per mRECIST as assessed by the investigator, or death due to any cause. It is assessed after TARE followed by durvalumab monotherapy followed by durvalumab + bevacizumab in participants with unresectable HCC amenable to locoregional therapy.

    Time frame: Time from first documented response until documented progression (Approximately 3 years)

07

Study locations

21 sites
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Gainesville, Florida 32608, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Boston, Massachusetts 02118, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Trenton, New Jersey 08690, United States
  • Research Site
    Buffalo, New York 14263, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Charlottesville, Virginia 22908, United States
  • Research Site
    Seattle, Washington 98195, United States
  • Research Site
    Milwaukee, Wisconsin 53215, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Publications

  • Pabon CM, Kumar-Sharma P, Spieler BO, Tuerff D, Datta J, Hosein PJ. Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy. Surg Oncol Clin N Am. 2026 Apr;35(2):347-365. doi: 10.1016/j.soc.2025.10.008. Epub 2026 Jan 14. PubMed 41903993 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jun 2026, 28 months.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 28 months is below that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 15, 2023
StartActual
Feb 13, 2024
Primary completionActual
Jun 30, 2026
CompletionEst.
May 27, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06040099
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 15, 2023
Start date
Feb 13, 2024
Primary completion
Jun 30, 2026
Completion
May 27, 2027 (estimated)
Last update
Sep 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Bevacizumab

Start the discussion